Table 1.

Timeline of FDA approvals and ACIP recommendations for the HPV vaccine in the United States.

Year	Month	Agency	Vaccine	Recommendation/Approval
2006	June	FDA	4vHPV	Approved vaccine for use in females 9–26 years of age
	June	ACIP	4vHPV	Recommended routine vaccine for females 11–12 years; catch-up 13–26 years; can be started at age 9
2009	October	FDA	2vHPV	Approved vaccine for use in females 10–25 years of age
	October	ACIP	2vHPV	Recommended vaccination for females 11–12 years; catch-up 13–26 years; can be started at age 9
	October	FDA	4vHPV	Approved vaccine for use males 9–26 years of age
	October	ACIP	4vHPV	Recommended vaccination may be given to males age 9–26 years – did not recommend routine vaccination
2011	October	ACIP	4vHPV	Recommended routine vaccination for males 11–12 years; catch-up 13–21 years and catch-up 22–26 years for men who have sex with men (MSM) or are immunocompromised; can be started at age 9
2014	December	FDA	9vHPV	Approved use in females 9–26 years of age
			9vHPV	Approved use in males 9–15 years of age
2015	February	ACIP	9vHPV	Recommended routine vaccination for females 11–12 years; catch-up 13–26 years; can be started at age 9
			9vHPV	Recommended routine vaccination for males 11–12 years; catch-up 13–21 years and catch-up 22–26 years for MSM and men who are immunocompromised; can be started at age 9
	December	FDA	9vHPV	Approved use in males 16–26 years of age
2016	October	FDA	9vHPV	Approved use of a two-dose option for males and females 9–14 years
	December	ACIP	9vHPV	Recommended two-dose option for males and females 9–14 years